The leader in pharma sales, Pfizer is well known thanks to several household name drugs, including Lipitor, Advil, Celebrex, Zithromax and the ever-abundant "little blue pill," Viagra. As the company looks at the looming Lipitor patent cliff, CEO Ian Read has been searching for new methods to keep revenue high, other than new approved drugs. Recently, the company has been considering spinning off portions of the company to create smaller, more profitable arms, a polar opposite of former CEO Jeffrey Kindler's bulk-up strategy of years past. The company's past purchases and mergers have included King Pharmaceuticals, Warner-Lambert, SUGEN and a $68 billion purchase, Wyeth, in 2009.

Wyeth provided Pfizer with an influx of 17 new drugs and vaccines, including Enbrel, Effexor, Prevnar and Pristiq, and Pfizer declared the merger made them "one of the most diversified companies in the global health care industry." And the company continues to move forward as it focuses on hot areas, including Alzheimer's, oncology and vaccines.

The company's legal woes have caused headaches as well. Pfizer has paid over $340 million in settlements for its menopause treatment, Prempro and has 1,200 cases pending for the anti-smoking drug Chantix. Back in 2009, it paid $1.3 billion for illegal marketing fines for the painkiller Bextra, making it the largest fine in United States history.

Pfizer has stayed in the top two on FiercePharma's annual layoffs list for the past three years, thanks in part to the company's 2009 megamerger with Wyeth, and the pressure could be felt for another five years. The company also placed second in the Top 15 R&D Budgets, with $7.4 billion in 2009. But those numbers will continue to slip as Pfizer looks towards development deals instead of in-house research.

Tag:

Pfizer

Latest Headlines

Latest Headlines

Earnings roundup: BMS to cut $1B more

Big Pharma inundated the market with earnings reports the last two days, for the most part surpassing analyst expectations. But the reports buried some of the biggest news: That Bristol-Myers Squibb

No more heli-commute perks for Pfizer SVP

SPOTLIGHT: No more heli-commute perks for Pfizer SVPShould a senior VP's helicopter commute go on the company dime? Pfizer's CEO Jeff Kindler apparently said no: HR exec Mary McLeod got a $300,000

Wyeth wrestles with Prempro suits

Two women in Nevada claimed that Prempro and Premarin led to them developing breast cancer, and rather than go to trial, Wyeth paid the women an undisclosed settlement amount. The women asserted

Pfizer plant in Michigan to cut 275

Pfizer is cutting 275 jobs at its biggest manufacturing plant in its latest restructuring move; the job eliminations in Kalamazoo, MI, will affect supervisory and support staff, and some operational

Psych meds find new market in pets

For the next new frontier in psychotropic drug sales, look no further than your best friend Rover. Pharma giants such as Pfizer, Eli Lilly, and Novartis are making big bucks reformulating and

Genentech, J&J earnings expected to rise

It's a big couple weeks for earnings, and so a couple of newspapers are offering a rundown on which pharma companies will report when and what results we're likely to see. Naturally, we're passing

Suicide widow sues Pfizer over Chantix

SPOTLIGHT: Suicide widow sues Pfizer over ChantixIt had to happen sometime: The widow of a man who shot himself in January has sued Pfizer, alleging that the drugmaker should have warned Chantix

Pharma giants to collaborate on new discovery tech

Three of the biggest pharma companies on the planet are joining forces to back an unusual venture aimed at developing "breakthrough" discovery technology that can reduce the frequency of trial

Pfizer: New users likely to stick to Lipitor

If you want to have your cake and take a pill to stave off ill effects on your cholesterol, Pfizer's Lipitor might be on your plate. It's the best selling drug in the world for a reason, and a new

Pfizer to stop funding for-profit CME

Drug companies have been catching flak lately not only for their direct payments and gifts to doctors-- such as speaking fees and travel-- but for funding the kind of continuing medical education